Checkpoint Therapeutics (NASDAQ:CKPT) Posts Earnings Results

Checkpoint Therapeutics (NASDAQ:CKPT) posted its quarterly earnings data on Tuesday. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08), Zacks reports.

Checkpoint Therapeutics Price Performance

Shares of CKPT stock traded up $0.16 on Thursday, reaching $3.78. 1,078,127 shares of the company were exchanged, compared to its average volume of 521,595. The company has a 50-day moving average of $2.79 and a 200-day moving average of $2.33. The company has a market cap of $170.17 million, a price-to-earnings ratio of -2.05 and a beta of 1.23. Checkpoint Therapeutics has a one year low of $1.36 and a one year high of $3.97.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a report on Thursday.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.